The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the …
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances …
The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
New blood biomarker data from Eli Lilly, Roche and Alamar Biosciences headline a London conference where non-amyloid mechanisms …
The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase …
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII replacement …
Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
Already a subscriber? Log in